NICE still developing Orphan drug methodology

David Haslam, new chairman of the National Institute for Health and Care Excellence, told BioCentury on Tuesday that the agency recognizes that its existing methodology for the cost utility analysis of drugs doesn't fit the Orphan drug model. On Monday, NICE officially took over responsibility...